Evidence map›Paper›PMID 42816649›Full record

ReviewNature reviews. Drug discovery2026

Soft drugs: design principles and topical applications.

Tracey Pirali, Alessandro Accetta, Jarkko Rautio, Laura Carzaniga

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tracey PiraliDepartment of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy.ORCID http://orcid.org/0000-0003-3936-4787
Alessandro AccettaMedicinal Chemistry and Drug Design Technologies Dept., Global Research and Development, Chiesi Farmaceutici S.p.A, Parma, Italy.ORCID http://orcid.org/0009-0004-0046-7636
Jarkko RautioSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.ORCID http://orcid.org/0000-0003-2172-3980
Laura CarzanigaMedicinal Chemistry and Drug Design Technologies Dept., Global Research and Development, Chiesi Farmaceutici S.p.A, Parma, Italy. l.carzaniga@chiesi.com.ORCID http://orcid.org/0000-0002-2426-1526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rational design of soft drugs has emerged as a powerful strategy to enhance drug safety, without compromising efficacy. Unlike conventional active pharmaceutical ingredients, soft drugs are deliberately designed to undergo predictable and rapid metabolic inactivation after exerting their therapeutic effect. Systemic soft drugs are particularly valuable in anaesthesiology, where rapid offset of action is desirable. Regarding topical administration, the soft drug approach enables potent local activity while minimizing systemic exposure and toxicity. However, despite these advantages and the market approval of several soft drugs, especially in dermatological, inhaled and gut-restricted therapies, the concept remains underutilized and often misunderstood, frequently being conflated with prodrugs. This Review revisits the concept of soft drugs from a modern perspective, clarifies its distinction from related approaches, highlights recent clinical successes in topical delivery, and provides practical insights into the application of soft drug design in drug discovery.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.